EMBO Molecular MedicineNeurosciencePeer-reviewed journal article
Molecular and cognitive signatures of ageing partially restored through synthetic delivery of IL2 to the brain
Pierre LemaîtreiD, Samar Hayat Khan TareeniD, Emanuela PasciutoiD, Loriana G. Mascali, Araks MartirosyaniD, Zsuzsanna Callaerts‐VeghiD, Suresh Kumar PoovathingaliD, James DooleyiD, Matthew G. HoltiD, Lidia YshiiiD, Adrian ListoniD
Abstract
Cognitive decline is a common pathological outcome during aging, with an ill-defined cellular or molecular basis. Among the cellular changes observed with age are alterations to neuronal plasticity, changes in the glial compartment and the decline of the neurogenic niche. In the recent years, the concept of inflammaging, defined as a low-grade inflammation increasing with age, has emerged as a nexus for age-related diseases. This increase of basal inflammation is also observed in the central nervous system. While not classically considered a neurological cell type, infiltrating T cells increase in the brain with age, and may be responsible for amplification of inflammatory cascades and disruptions to the neurogenic niche. Recently, a small resident population of regulatory T cells has been identified in the brain, and the capacity of IL2-mediated expansion of this population to counter neuroinflammatory disease has been demonstrated. Here we test a brain-specific IL2 delivery system for the prevention of neurological decline in aging mice. We identify the molecular hallmarks of aging in the brain glial compartments, and identify partial restoration of this signature through IL2 treatment. At a behavioral level, brain IL2 delivery prevented the age-induced defect in spatial learning, without improving the general decline in motor skill or arousal. These results identify immune modulation as a potential path to preserving cognitive function for healthy ageing.
- organism: mouse
- assay: proteomics
- assay: spatial transcriptomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 34
- FWCI
- 3.29
- Field percentile
- top 7%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CAR T cell targeting of inflammatory myeloid progenitors in the bone marrow remodels border-associated macrophages and reverses cognitive aging
Alexander S. Harris, James A. Rouse, … Corina Amor·bioRxiv·Sep 28, 2026
- Chronic IL-6 overproduction induces a tolerogenic response in aged mice after peripheral nerve injury
Gemma Manich, Ruggero Barbanti, … Bernardo Castellano·bioRxiv·Mar 13, 2024
- Fate-mapping and functional dissection reveal perilous influence of type I interferon signaling in mouse brain aging
Ethan R. Roy, Sanming Li, … Wei Cao·Molecular NeurodegenerationPeer-reviewed·Jun 17, 2024
- Necroptosis inhibition counteracts neurodegeneration, memory decline and key hallmarks of aging, promoting brain rejuvenation.
Macarena S. Arrázola, Matías Lira, … Felipe A. Court·Aging CellPeer-reviewed·Mar 27, 2023
- Age-related inflammatory changes and perineuronal net dynamics: implications for neurodegenerative disorders.
Zachary A. Colon, Shannon C. Chan, Kathleen A. Maguire‐Zeiss·bioRxiv·Sep 10, 2025
- Lymphatic CD49a is a driver of meningeal immune aging and cognitive decline.
Natalie M. Frederick, Rachel A. Tinkey, … Antoine Louveau·bioRxiv·Aug 9, 2026